Oral cancer point of care diagnostics
AssigneesWilliam Marsh Rice University, The University of Sheffield, Board of Regents, The University of Texas System
InventorsJohn T. McDevitt, Nicolaos Christodoulides, Pierre N. Floriano, Martin Thornhill, Spencer Redding, Nadarajah Vigneswaran, Craig Murdoch, Paul Speight
Life of this patent
Estimating the term…
Abstract
A point of care diagnostic test, device and disposables for determining a patient risk for oral cancer in the same visit that a sample is collected.
Claims21
1) A disposable cassette comprising a planar surface having a sample port for applying a patient sample thereto, said sample port fluidly connected to a detection window, said detection window having a membrane for collecting cells, said planar support also having at least one reagent chamber thereon containing reagents wherein said reagent chamber is upstream and fluidly connected to said detection window, said reagents including at least a DNA stain, a cytoplasmic stain, and antibodies specific for at least three biomarkers selected from AVB6 beta6, EGFR, Ki67, Geminin, MCM2, Beta Catenin, and EMMPRIN.
8) A disposable cassette comprising a planar surface having a sample port, a wash chamber, a reagent chamber, a detection window comprising a cell trapping membrane, wherein said sample port is upstream and fluidly connected to said detection window, and wherein said wash chamber and said reagent chamber are upstream and fluidly connected to said detection window, and wherein said waste chamber is downstream and fluidly connected to said detection window, said reagent chamber thereon containing a least a DNA stain, a cytoplasmic stain, and antibodies specific for at least two biomarkers selected from alphaV beta6 (AVB6), Epidermal Growth Factor Receptor (EGFR), Ki67, Geminin, Mini Chromosome Maintenance protein (MCM2), beta catenin, and EMPPRIN.
13) A test for detecting oral cancer, wherein the test measures:
- a) morphological characteristics selected from nuclear area, nuclear diameter, cell area, cell diameter, cytoplasmic area ratio, cell circularity, cell aspect ratio and cell roundness;
- and
- b) at least one biomarker selected from the group consisting of AVB6, EGFR, Ki67, Geminin, MCM2, beta catenin, and EMPPRIN;
- c) wherein said test is on performed on a single portable device comprising one or more disposable chips comprising reagents for detecting DNA, cytoplasm, and said at least one biomarker;
- and
- d) wherein the risk of oral cancer is directly proportional to nuclear/cytoplasmic area ratio, cell circularity, cell roundness, EGFR, KI67, Geminin, AVB6, MCM2, beta catenin and EMMPRIN and inversely correlated with cell aspect ratio.
19) A method of point of care testing to distinguishing oral cancer from dysplasia and benign lesions, said method comprising:
- a) collecting an oral sample from a patient during a patient visit using a rotating brush;
- b) applying said sample to a portable device comprising microfluidics, a power source electronics, display means and a removable, disposable chip comprising reagents for detecting DNA, cytoplasm, and at least three biomarkers selected from AVB6, EGFR, Ki67, Geminin, MCM2, Beta Catenin, and EMMPRIN;
- c) wherein said device measures nuclear/cytoplasm ratio and cell shape, and said at least three biomarkers in said sample;
- d) wherein said device measures computes the risk of oral cancer based on said measurements wherein risk of oral cancer is directly proportional to nuclear/cytoplasmic area ratio, cell roundness, EGFR, KI67, Geminin, AVB6, MCM2, beta catenin ands EMMPRIN and inversely correlated with cell aspect ratio and the risk of benign lesions is the reverse;
- and
- e) wherein said device measures communicates said risk to the patient in the same patient visit as said collecting step a).
Dependencies are inferred from the claim text.